ClinicalTrials.gg
RecruitingNCT07594119FOCUS 2Updated Nov 16, 2026

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

A Phase 3 interventional study of RAP-219 and RAP-219 in Focal Seizure, Epilepsy and Focal Epilepsy, sponsored by Rapport Therapeutics Inc.. Recruiting at 14 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Rapport Therapeutics Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 16, 2026First sites in Australia and South Korea18 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Planned enrollment
35th of 306
312 · median 56
Started
2026
with 14 others
Phase 3
84 of 395
15 open now
Primary completion
2029-07
later than 74 of 91 live
Registered
387th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 35th largest by planned enrollment of the 306 interventional ones that give a count, is one of 15 that started in 2026, is one of 84 in phase 3, reaches primary completion later than 74 of the 91 other live ones, and was the 387th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Read the detailed description

Approximately 312 subjects will be randomized into one of two active treatment groups or placebo in a 1:1:1 randomization ratio (Medium Dosage, Low Dosage and Placebo). After completing the Double-blind Treatment Period, participants will either transition into the RAP-219-FOS-901 long-term safety (open-label extension) study or enter the 8-week post-treatment Follow-up Period of this study.

03

Conditions studied

  • Focal Seizure
  • Epilepsy
  • Focal Epilepsy

Keywords

  • Focal Preserved Consciousness
  • Focal Impaired Consciousness
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 - 75
  2. 18-45 kg/m2
  3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1
  4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis
  5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs
  6. Ability to keep accurate daily focal seizure records using an e-diary

Exclusion criteria

Exclusion Criteria:

  1. Known or prior exposure to RAP-219.
  2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur
  3. Anticipated need for surgery during the study period
  4. Medical history of any of the following:

    1. generalized epilepsy
    2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type
    3. psychogenic nonepileptic seizure (PNES)
    4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).
    5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).
  5. Participation in another clinical study of an product within 12 weeks or 5 half-lives of this other investigational product
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    Active Arm- Medium Dose

    RAP-219 daily tablets administered orally

    Drug: RAP-219

  • Experimental
    Active Arm-Low Dose

    RAP-219 daily tablets administered orally

    Drug: RAP-219

  • Placebo comparator
    Placebo

    Inert comparator matching the active treatment

    Other: Placebo

Interventions

  • RAP-219 medium dose tablets administered orally daily

  • RAP-219 low dose tablets administered orally daily

  • OtherPlacebo

    Matching placebo tablets administered orally

06

What researchers measure

Primary outcomes

  1. Median Percent Change in Seizure Frequency

    Median percent change in seizure frequency and ≥ 50% seizure frequency reduction responder rates

    Time frame: End of double-blind treatment period (end of week 14) vs Baseline

Secondary outcomes

  1. ≥50% seizure frequency reduction responder rates

    Proportion of participants with at least 50% reduction from baseline in seizure frequency after treatment with RAP-219 compared with placebo

    Time frame: End of double-blind treatment period (end of week 14) vs Baseline.

  2. Longest Seizure Free Interval

    To evaluate the longest seizure-free interval after treatment with RAP-219 compared with placebo

    Time frame: Across the entire 14-week double-blind treatment period

Other outcomes

  1. Incidence of Adverse Events

    incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs leading to discontinuation

    Time frame: From Visit 1 through End of Study, on average Week 22.

07

Study locations

14 of 14 sites recruiting
  • Clinical Study Center
    Huntsville, Alabama 35801, United States
    Recruiting
  • Clinical Study Center
    Bentonville, Arkansas 72712, United States
    Recruiting
  • Clinical Study Center
    Colorado Springs, Colorado 80919, United States
    Recruiting
  • Clinical Study Center
    Maitland, Florida 32751, United States
    Recruiting
  • Clinical Study Center
    Miami, Florida 33176, United States
    Recruiting
  • Clinical Study Center
    Honolulu, Hawaii 96817, United States
    Recruiting
  • Clinical Study Center
    Chicago, Illinois 60611, United States
    Recruiting
  • Clinical Study Center
    Omaha, Nebraska 68105, United States
    Recruiting
  • Clinical Study Center
    New York, New York 10075, United States
    Recruiting
  • Clinical Study Center
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Clinical Study Center
    Nashville, Tennessee 37179, United States
    Recruiting
  • Clinical Study Center
    Houston, Texas 77030, United States
    Recruiting
  • Clinical Study Center
    Melbourne, Australia
    Recruiting
  • Clinical Study Center
    Seoul, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2029, 34 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's planned 34 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Sep 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added, 15 sites removed — first sites in Australia and South Korea
Show 18 added (14 United States, 2 Australia, 2 South Korea)
  • Hawaii Pacific Neuroscience · Honolulu, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Eastern Health Clinical School, Monach University Box Hill · Melbourne, Australia
  • Samsung Medical Center · Seoul, South Korea
  • Clinical Study Center · Huntsville, United States
  • Clinical Study Center · Bentonville, United States
  • Clinical Study Center · Colorado Springs, United States
  • Clinical Study Center · Maitland, United States
  • Clinical Study Center · Miami, United States
  • Clinical Study Center · Honolulu, United States
  • Clinical Study Center · Chicago, United States
  • Clinical Study Center · Omaha, United States
  • Clinical Study Center · New York, United States
  • Clinical Study Center · Raleigh, United States
  • Clinical Study Center · Nashville, United States
  • Clinical Study Center · Houston, United States
  • Clinical Study Center · Melbourne, Australia
  • Clinical Study Center · Seoul, South Korea
Show 15 removed
  • Clinic for Neurology · Huntsville, United States
  • Pillar Clinical Research · Bentonville, United States
  • Colorado Springs Neurological Associates · Colorado Springs, United States
  • K2 Medical Research · Maitland, United States
  • Serenity Research Center, LLC · Miami, United States
  • Hawaii Pacific Neuroscience · Honolulu, United States
  • Re:Cognition Health-Chicago · Chicago, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Lenox Hill Hospital · New York, United States
  • Velocity Clinical Research · Raleigh, United States
  • Vanderbilt University Medical Center · Nashville, United States
  • Baylor College of Medicine · Houston, United States
  • University of Texas Health Science Center in Houston · Houston, United States
  • Eastern Health Clinical School, Monach University Box Hill · Melbourne, Australia
  • Samsung Medical Center · Seoul, South Korea
across 4 updates, Oct 15, 2026 – Nov 16, 2026
Show all 4 updates
  1. Nov 16, 2026
    14 sites added, 15 sites removed
    Show 14 added (12 United States, 1 Australia, 1 South Korea)
    • Clinical Study Center · Huntsville, United States
    • Clinical Study Center · Bentonville, United States
    • Clinical Study Center · Colorado Springs, United States
    • Clinical Study Center · Maitland, United States
    • Clinical Study Center · Miami, United States
    • Clinical Study Center · Honolulu, United States
    • Clinical Study Center · Chicago, United States
    • Clinical Study Center · Omaha, United States
    • Clinical Study Center · New York, United States
    • Clinical Study Center · Raleigh, United States
    • Clinical Study Center · Nashville, United States
    • Clinical Study Center · Houston, United States
    • Clinical Study Center · Melbourne, Australia
    • Clinical Study Center · Seoul, South Korea
    Show 15 removed
    • Clinic for Neurology · Huntsville, United States
    • Pillar Clinical Research · Bentonville, United States
    • Colorado Springs Neurological Associates · Colorado Springs, United States
    • K2 Medical Research · Maitland, United States
    • Serenity Research Center, LLC · Miami, United States
    • Hawaii Pacific Neuroscience · Honolulu, United States
    • Re:Cognition Health-Chicago · Chicago, United States
    • University of Nebraska Medical Center · Omaha, United States
    • Lenox Hill Hospital · New York, United States
    • Velocity Clinical Research · Raleigh, United States
    • Vanderbilt University Medical Center · Nashville, United States
    • Baylor College of Medicine · Houston, United States
    • University of Texas Health Science Center in Houston · Houston, United States
    • Eastern Health Clinical School, Monach University Box Hill · Melbourne, Australia
    • Samsung Medical Center · Seoul, South Korea
  2. Nov 12, 2026
    1 site added — first site in South Korea
    Show site
    • Samsung Medical Center · Seoul, South Korea
  3. Nov 6, 2026
    1 site added — first site in Australia
    Show site
    • Eastern Health Clinical School, Monach University Box Hill · Melbourne, Australia
    + 2 other changes: verification date and date precision
  4. Oct 15, 2026
    2 sites added
    Show 2 added (2 United States)
    • Hawaii Pacific Neuroscience · Honolulu, United States
    • University of Nebraska Medical Center · Omaha, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07594119
Lead sponsor
Rapport Therapeutics Inc.
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Sep 1, 2026
Primary completion
Jul 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Rapport Medical
Contact
RAP-219-FOS@rapportrx.com
857 323 9048
Vicente Villaneuva, M.D., PhD
principal investigator · Hospital Universitari i Politecnic La Fe, Spain

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RAP-219

Start the discussion